Clinical trials located in

Włocławek

Włocławek city is located in Poland. Currently, 8 clinical trials are being conducted in this city.

Włocławek, located on the Vistula River in Poland, is a city steeped in history and culture. Established in the 12th century, it boasts one of the oldest cathedrals in the country, the Włocławek Cathedral, showcasing Gothic architecture. The city is also known for its unique hydraulic engineering monument, the Włocławek Dam, the first dam in Poland, built in the 1960s. Włocławek has a rich tradition in ceramics, with its Museum of the Kujawy and Dobrzyń Land featuring an extensive collection of local pottery. The city’s vibrant past and contributions to Polish culture make it a notable location in the country’s landscape.

  • CT-EU-00057209

    Study on a new combination therapy for active ulcerative colitis

    This study aims to assess the effectiveness and safety of new combination therapy with JNJ-78934804 (Guselkumab/Golimumab) in comparison to guselkumab and golimumab administred alone for individuals with moderately to severely active ulcerative colitis. Participants who have shown inadequate response, loss of response, or intolerance to approved advanced therapies will be included. The trial includes various treatment groups: placebo, Guselkumab, Golimumab, and different doses of JNJ-78934804. All participants meeting inadequate response criteria will be escalated to an active treatment. The study will last for 48 weeks and the progress will be tracked over this period. The primary focus is to evaluate the efficacy and safety of the different doses of new therapy in managing ulcerative colitis over the course of the study.

    • JNJ-78934804/guselkumab + golimumab
    • Golimumab
    • Guselkumab
  • Exploring the effect and safety of a new treatment for Severe Ulcerative Colitis

    This clinical trial aims to explore the potential of NX-13, a new oral medication, in providing relief to adults suffering from moderate to severe ulcerative colitis, a chronic condition that causes inflammation and ulcers in the digestive tract, leading to discomfort and other debilitating symptoms. The study is designed to test two different doses of NX-13, 250mg and 750mg, comparing them with a placebo to determine the medication’s effectiveness in managing the symptoms of this condition.

    Participants in the study will be carefully monitored to assess how well NX-13 controls the inflammation and symptoms associated with ulcerative colitis, and to ensure the safety and tolerability of the medication. The study also aims to understand the long-term impacts of the medication, with an extension period included to gather more comprehensive data on its sustained effects.

    • Amelenodor/NX-13
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Combination therapy trial for moderately to severely active Crohn’s disease

    The study examines a combination therapy using guselkumab and golimumab in individuals with active Crohn’s Disease. It aims to compare the effectiveness of this dual approach to individual treatments, focusing on reducing disease symptoms and improving patients’ quality of life. The study’s goal is to offer new hope and better management strategies for those battling this challenging condition.

    • JNJ-78934804 (guselkumab, golimumab)
    • Golimumab
    • Guselkumab
  • Looking into the impact of the new drug on Crohn’s disease

    The research study ‘STENOVA’ is aimed at evaluating the safety and effect of a new medication, AGMB-129, on patients with Fibrostenotic Crohn’s Disease, a specific type of digestive illness. The study has three primary objectives: first, to assess the safety of AGMB-129 for patient consumption; second, to investigate the pharmacokinetics, which is how the body processes the drug; and third, to explore the pharmacodynamics, or the effect of the drug on the body. Participants in the study are required to commit to a duration of approximately 19 weeks. During this period, they will receive either a high dose, a low dose, or a placebo of AGMB-129. The placebo is a harmless substance that has no effect on the body. The study is structured to blind participants to the specific treatment they receive, to maintain unbiased results. In addition to taking the medication, participants will undergo various checkups and tests. These procedures are designed for continuous monitoring and evaluation of the drug’s effects and the participants’ health throughout the study.

    • AGMB-129- new potential medication for Fibrostenosing Crohn’s Disease
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Poland:

.